^
    Back
    Association details:
    Biomarker:MTAP deletion
    Cancer:Solid Tumor
    Drug:TNG908 (PRMT5 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

    Excerpt:
    ...Documented bi-allelic (homozygous) deletion of MTAP in a tumor detected by next- generation sequencing or absence of MTAP protein in a tumor detected by IHC....
    Trial ID:
    NCT05275478
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2022
    Title:

    3941 / 15 - TNG908 is an MTAPnull-selective PRMT5 inhibitor that drives tumor regressions in MTAP-deleted xenograft models across multiple histologies

    Published date:
    03/09/2022
    Excerpt:
    In summary, TNG908 is a novel, potent PRMT5 inhibitor with excellent drug-like properties and strong preclinical activity in multiple xenograft models that has the potential for histology-agnostic clinical development in MTAP-deleted solid tumors.